Avantor (AVTR) Stock Shrugs Off Q3 Earnings As Debt Stays Central

Avantor just posted its Q3 2026 scorecard and the stock barely flinched. Shares slipped 0.06% to US$16.68, a flat reaction to what was, on the surface, a sharp earnings rebound. Basic earnings per share landed at about US$0.30 on US$1.70b in sales, a far cleaner print than recent quarters.

The market still treats Avantor as a slow grind recovery story. The quarter instead put the spotlight on a different issue that matters more right now: the balance sheet and the strain from carrying debt against only recently restored profitability.

Love Avantor's cleaner earnings print but worried about the debt load now that profitability is back on the table? Check out a list of solid balance sheet and fundamentals stocks (22 results) to see how other companies pair earnings power with sturdier finances.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1,698.3m vs. US$1,623.8m (up about 4.6%)
• Net Income, Excluding Extra Items (Q3 2026 vs. Q3 2025): US$203.4m vs. a loss of US$711.8m (swing back to profit)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.30 vs. a loss of US$1.04 per share (return to positive earnings per share)
• Adjusted EBITDA Margin (Q3 2026): US$257m adjusted EBITDA on US$1,698.3m revenue (15.1% margin, company reported)

Ask Charlie what made Avantor raise guidance after Revival progress.

Avantor Revival Delivers Tangible Turnaround Milestones

The bullish pitch around Avantor is that better execution, not just healthier labs demand, can rebuild growth, margins and cash generation.

"Revival driven improvements in execution, throughput and commercial discipline that already show up in sequential EBITDA growth above 15% from Q1 to Q2 2026 could create further room for Avantor to lift earnings and free cash flow without relying on faster end markets."

Q3 puts clearer proof points on that claim. Organic revenue rose 5.2% with both VWR and Bioscience & MedTech Products back in positive territory. About half of VWR’s 5.8% organic lift is credited to Revival actions, while BMP margins held at 26.6%. Management also raised 2026 EPS and free cash flow guidance and cut net debt by US$173m, which directly ties operational gains to stronger cash and leverage metrics.

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all.

Avantor: Order Momentum Meets Patchy Conversion Progress

Bearish research argues that Avantor’s Revival wins will not show up cleanly in reported growth or profitability.

"Despite double digit order growth and a 1.1x book to bill ratio in Bioscience & Medtech Products, the combination of ongoing organic revenue decline and external research pointing to share loss in VWR with forecasts for flat revenue over the next 12 months raises the risk that order strength does not convert into sustained top line growth or improved EBITDA margin."

Q3 pushes back on the idea of ongoing strain. Both VWR and Bioscience & MedTech Products posted organic expansion and solid margins, and company guidance now points to positive full year organic growth and higher adjusted EPS. The miss against the bearish script is that conversion is happening, just not yet at a pace that removes execution risk.

Hunt Quiet Mispricings Before They Fade

Avantor just reminded investors that earnings progress does not always move the share price. The real opportunity is spotting companies that could be undervalued before the market fully closes the gap.

• Company 1 - 36% below our estimate - uses a record power systems run and new capacity to pursue data center engine contracts.
• Company 2 - 26% below our estimate - positions critical chips and software at key data chokepoints across digital infrastructure.
• Company 3 - 23% below our estimate - turns a cloud platform, AI tools and workplace software into one ecosystem for enterprise workflows.

Three companies from the same screener. Open every one of the 30 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com